MPR Weekly Dose 84 - Emergency Use for COVID-19 treatment; Fact sheet update for vaccines; Rylaze approved; Expanded approval for Solosec; NDA submitted for HIV-1 treatment

The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. Revisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Solosec gets an expanded indication and a new drug application for a HIV-1 treatment has been submitted.